Cargando…

A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis

The PROteKT study tested the hypothesis that rosuvastatin can inhibit aminoglycoside-induced nephrotoxicity in children with Cystic Fibrosis (CF). This open label, parallel group, randomised controlled trial recruited children and young people aged 6 to 18 years with CF at 13 paediatric CF treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	McWilliam, Stephen J., Rosala-Hallas, Anna, Jones, Ashley P., Shaw, Victoria, Greenhalf, William, Jaki, Thomas, Smyth, Alan R., Smyth, Rosalind L., Pirmohamed, Munir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000680/ https://www.ncbi.nlm.nih.gov/pubmed/32020028 http://dx.doi.org/10.1038/s41598-020-58790-1

Ejemplares similares

Author Correction: A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis
por: McWilliam, Stephen J., et al.
Publicado: (2020)

Urinary Biomarkers of Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin
por: McWilliam, Stephen J., et al.
Publicado: (2018)

Aminoglycoside-induced nephrotoxicity in children
por: McWilliam, Stephen J, et al.
Publicado: (2016)

Mechanism-Based Urinary Biomarkers to Identify the Potential for Aminoglycoside-Induced Nephrotoxicity in Premature Neonates: A Proof-of-Concept Study
por: McWilliam, Stephen J., et al.
Publicado: (2012)

Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis
por: Prayle, Andrew, et al.
Publicado: (2010)

Feasibility study to inform the design of a randomised controlled trial to eradicate Pseudomonas aeruginosa infection in individuals with Cystic Fibrosis
por: Hickey, Helen R, et al.
Publicado: (2010)

Comparing cystic fibrosis outcomes across the pond
por: Taylor-Robinson, David C, et al.
Publicado: (2015)

The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison
por: Prayle, A.P., et al.
Publicado: (2016)

A pilot randomised controlled trial to assess the utility of an e‐learning package that trains users in adverse drug reaction causality
por: Conroy, Elizabeth J., et al.
Publicado: (2015)

A Longitudinal Study of the Impact of Social Deprivation and Disease Severity on Employment Status in the UK Cystic Fibrosis Population
por: Taylor-Robinson, David C., et al.
Publicado: (2013)

The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study
por: Taylor-Robinson, David C, et al.
Publicado: (2013)

Delayed publication of clinical trials in cystic fibrosis()
por: Hurley, M.N., et al.
Publicado: (2012)

Repurposing Statins for Renal Protection: Is It a Class Effect?
por: McWilliam, Stephen J., et al.
Publicado: (2017)

Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial
por: Hewer, Simon C Langton, et al.
Publicado: (2020)

Understanding the natural progression in %FEV(1) decline in patients with cystic fibrosis: a longitudinal study
por: Taylor-Robinson, David, et al.
Publicado: (2012)

Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis
por: Hurley, Matthew N., et al.
Publicado: (2012)

Low socioeconomic status is associated with worse lung function in the Danish cystic fibrosis population
por: Taylor-Robinson, David C., et al.
Publicado: (2014)

The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome
por: Sexton, Travis R., et al.
Publicado: (2014)

Future therapies for cystic fibrosis
por: Allen, Lucy, et al.
Publicado: (2023)

Enhancing Communication about Paediatric Medicines: Lessons from a Qualitative Study of Parents' Experiences of Their Child's Suspected Adverse Drug Reaction
por: Arnott, Janine, et al.
Publicado: (2012)

A review of recruitment of children to randomised clinical trials in the NIHR clinical research network portfolio
por: Kaur, Geetinder, et al.
Publicado: (2013)

Family‐centred care in cystic fibrosis: a pilot study in North Queensland, Australia
por: Smyth, Wendy, et al.
Publicado: (2017)

1078. Expectations and Attitudes Toward Antimicrobial Stewardship Among Cystic Fibrosis Care Providers
por: Bullington, Wendy, et al.
Publicado: (2019)

Development of the Liverpool Adverse Drug Reaction Avoidability Assessment Tool
por: Bracken, Louise E., et al.
Publicado: (2017)

The relationship between the structure and toxicity of aminoglycoside antibiotics
por: Jospe-Kaufman, Moriah, et al.
Publicado: (2020)

A refresh of the top 10 research priorities in cystic fibrosis
por: Rowbotham, Nicola Jane, et al.
Publicado: (2023)

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis
por: Floto, R Andres, et al.
Publicado: (2016)

Extended-Interval Aminoglycoside Use in Cystic Fibrosis Exacerbation in Children and Young Adults: A Prospective Quality Improvement Project
por: Safi, Khalid H., et al.
Publicado: (2016)

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis()
por: Hurley, M.N., et al.
Publicado: (2012)

Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis()
por: Qvist, Tavs, et al.
Publicado: (2016)

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study()
por: Forrester, Doug L., et al.
Publicado: (2013)

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary
por: Floto, R Andres, et al.
Publicado: (2016)

Pharmacogenetics of warfarin in a paediatric population: Time in therapeutic range, initial and stable dosing, and adverse effects
por: Hawcutt, Daniel B, et al.
Publicado: (2014)

Potentiating aminoglycoside antibiotics to reduce their toxic side effects
por: Rosenberg, Christopher R., et al.
Publicado: (2020)

Toxic Goitre
por: Smyth, J. A.
Publicado: (1933)

Growth of HIV-exposed uninfected, compared with HIV-unexposed, Zambian children: a longitudinal analysis from infancy to school age
por: Rosala-Hallas, Anna, et al.
Publicado: (2017)

Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome
por: Marsh, Ryan, et al.
Publicado: (2023)

A prospective randomised controlled mixed-methods pilot study of home monitoring in adults with cystic fibrosis
por: Nash, Edward F., et al.
Publicado: (2022)

Perception of first respiratory infection with Pseudomonas aeruginosa by people with cystic fibrosis and those close to them: an online qualitative study
por: Palser, Sally C, et al.
Publicado: (2016)

In vitro Activity of Ceftolozane/Tazobactam Alone or with an Aminoglycoside Against Multi-Drug-Resistant Pseudomonas aeruginosa from Pediatric Cystic Fibrosis Patients
por: Dassner, Aimee M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9mhdrdqbu03kg11qupjg6bfqss